EU/3/06/360

  • Email
  • Help

Orphan designation

On 6 April 2006, orphan designation (EU/3/06/360) was granted by the European Commission to Novagali Pharma, France, for ciclosporin for the treatment of vernal keratoconjunctivitis.

What is vernal keratoconjunctivitis?

Vernal keratoconjunctivitis (also known as spring catarrh) is a chronic allergic inflammation (swelling and redness) of the conjunctiva (membrane lining the eyelid and covering the eyeball) and the cornea (clear tissue in the front of the eye that protects deeper structures), most often seen in young children and with seasonal appearance. This inflammation leads to redness, fluid discharge, itching, pain and light sensitivity.

Vernal keratoconjunctivitis is often seen together with other allergic conditions (e.g. eczema and asthma). The condition is chronically debilitating due to possible corneal ulcers and visual loss.

What is the estimated number of patients affected by the condition?

At the time of designation, vernal keratoconjunctivitis affected between 1 to 3 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 46,000 to 138,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed based on data from the European Union (EU 25), Norway, Iceland and Liechtenstein. This represents a population of 459,700,000 (Eurostat 2004).

What treatments are available?

Some medicinal products were authorised for the treatment of vernal keratoconjunctivitis in the Community at the time of submission of the application for orphan drug designation.
Satisfactory argumentation has been submitted by the sponsor to justify that ciclosporin might be of potential significant benefit for the treatment of vernal keratoconjunctivitis because it may bring better control of the symptoms of the condition. These benefits will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.

How is this medicine expected to work?

Ciclosporin is an immunosuppressant drug; it inhibits the function of the cells of the immune system (body’s defence to infection and disease). In patients with vernal keratoconjunctivitis it is expected to prevent the inflammation observed in conjuctiva and cornea.

What is the stage of development of this medicine?

The effects of ciclosporin have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials in patients with vernal keratoconjunctivitis were ongoing.

Ciclosporin was not authorised anywhere worldwide for vernal keratoconjunctivitis or designated as orphan medicinal product elsewhere for this condition, at the time of submission.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 8 March 2006 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria: 
  • the seriousness of the condition;
  • the existence of alternative methods of diagnosis, prevention or treatment;
  • and either the rarity of the condition (affecting not more than five in 10,000 people in the Community) or the insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

Key facts

Product details for <p>Ciclosporin</p>
Active substanceCiclosporin
Medicine Name
Disease/conditionTreatment of vernal keratoconjunctivitis
Date of decision06/04/2006
OutcomePositive
Orphan decision numberEU/3/06/360

Review of designation

Related information

Sponsor’s contact details:

Novagali Pharma
Bât Genavenir IV
1, rue Pierre Fontaine
91 058 EVRY Cedex
France
Telephone: +33 1 69 87 40 23
Telefax: +33 1 69 87 40 20
E-mail: contact@novagali.com

Patients’ organisations:

For contact details of patients’ organisations whose activities are targeted at rare diseases see:

  • Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.